This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
==== Ferrous iron uptake via protein transporters in land plants and chlorophytes ==== Distant homologues of the metal ion transporters ZIP in land plants and chlorophytes have converged in structure, likely to take up Fe2+ efficiently. The IRT1 proteins from Arabidopsis thaliana and rice have extremely different amino acid sequences from Chlamydomonas's IRT1, but their three-dimensional structures are similar, suggesting convergent evolution.
If the incircle is tangent to the sides AB, BC, CD, DA at T1, T2, T3, T4 respectively, and if N1, N2, N3, N4 are the isotomic conjugates of these points with respect to the corresponding sides (that is, AT1 = BN1 and so on), then the Nagel point of the tangential quadrilateral is defined as the intersection of the lines N1N3 and N2N4. Both of these lines divide the perimeter of the quadrilateral into two equal parts. More importantly, the Nagel point N, the "area centroid" G, and the incenter I are collinear in this order, and NG = 2GI. This line is called the Nagel line of a tangential quadrilateral. In a tangential quadrilateral ABCD with incenter I and where the diagonals intersect at P, let HX, HY, HZ, HW be the orthocenters of triangles AIB, BIC, CID, DIA. Then the points P, HX, HY, HZ, HW are collinear.
Dwarfism is a condition marked by the unusually small size or short stature of individual animals. In humans, it is defined as an adult height of 147 centimetres (4 ft 10 in) or less, regardless of sex; the average adult height among people with dwarfism is 120 centimetres (4 ft). Disproportionate dwarfism is characterized by either short limbs or a short torso. In cases of proportionate dwarfism, both the limbs and torso are unusually small. Intelligence is usually normal, and most people with it have a nearly normal life expectancy. People with dwarfism can usually bear children, although there are additional risks to the mother and child depending upon the underlying condition. The most common and recognizable form of dwarfism in humans (comprising 70% of cases) is achondroplasia, a genetic disorder whereby the limbs are diminutive. Growth hormone deficiency is responsible for most other cases. There are many other less common causes. Treatment of the condition depends on the underlying cause. Those with genetic disorders such as osteochondrodysplasia can sometimes be treated with surgery or physical therapy. Hormone disorders can also be treated with growth hormone therapy before the child's growth plates fuse. Individual accommodations, such as specialized furniture, are often used by people with dwarfism. Many support groups provide services to aid individuals and the discrimination they may face. In addition to the medical aspect of the condition there are social aspects.
== Receptors == The major cell-matrix adhesion receptors are integrins and therefore the adhesome of cell-matrix adhesion is referred to as the integrin adhesome. Cell-cell adhesion is primarily mediated by cadherin receptors and therefore the adhesome of cell-cell adhesion is referred to as the cadherin adhesome or cadhesome. The first attempts to establish the set of proteins that participate directly ('bona fide' adhesome components) or affect indirectly ('associated' adhesome components) cell adhesion were based on mining of the primary research literature, and resulted in approximately 200 protein in either integrin or cadherin adhesomes. Later, unbiased proteomic approaches utilizing mass spectrometry have detected hundreds more proteins associated with integrin adhesions. However, a comparison of multiple proteomic studies of the integrin adhesome of fibroblasts attached to fibronectin found only 60 proteins common to all studies.
Sources: en.wikipedia.org
=== Genetic influence and environmental factors === Various studies have found direct genetic effects to account for at least 46% of the variation of timing of puberty in well-nourished populations. The genetic association of timing is strongest between mothers and daughters. The specific genes affecting timing are not yet known. Among the candidates is an androgen receptor gene. Researchers have hypothesized that early puberty onset may be caused by certain hair care products containing estrogen or placenta, and by certain chemicals, namely phthalates, which are used in many cosmetics, toys, and plastic food containers.
=== Separation of powers of the federal and state governments === The federation agreement (Perjanjian Persekutuan) set the powers of the federal and state governments. Financial matters must be handled by the respective states. The Sultan was given full power on religious issues and Malay customs. Foreign policy and defence continued to be administered by the British government. The federation agreement was made the Constitution of the Federation of Malaya and officially declared on 1 February 1948.
Pro-inflammatory cytokines IFN-γ, IFN-α, TNF-α, IL-6 and IL-17 have been shown to promote autistic behaviors in animal models. Giving anti-IL-6 and anti-IL-17 along with IL-6 and IL-17, respectively, have been shown to negate this effect in the same animal models. Some gut proteins and microbial products can cross the blood–brain barrier and activate mast cells in the brain. Mast cells release pro-inflammatory factors and histamine which further increase blood–brain barrier permeability and help set up a cycle of chronic inflammation.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.